Glioblastoma Multiforme Market is predicted to reach USD 5.65 billion at a CAGR of 8.52% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Glioblastoma Multiforme Market”.

The Glioblastoma Multiforme Market is expected to register a CAGR of 8.52% during the forecast period 2023-2032, to reach USD 5.65 billion by 2032.

MRFR recognizes the following companies as the key players in the Global Glioblastoma Multiforme Market — Merck & Co., Inc (US), Amgen, Inc (US), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc (US), AstraZeneca (UK), Eli Lilly and Company (US), VBI Vaccines Inc. (US), and AbbVie Inc. (US).

Market Highlights

The global glioblastoma multiforme market is expected to have a market value of USD 5.65 billion by 2032.

The global glioblastoma multiforme market is driven by several factors, an increasing incidence of glioblastoma multiforme globally, and increased awareness. According to the American Association of Neurological Surgeons by June 2021 the most frequent malignant brain and other CNS tumor is glioblastoma, which accounts for 47.7% of all cases. The incidence of glioblastoma is 3.21 per 100,000 people. Furthermore, The diagnosis is more prevalent in males than in women, with a median age of 64. About 40% of patients survive in the first year following diagnosis and 17% in the second. Also, increasing research and development activity is driving the growth of the market. However, regulatory barriers are hampering the growth of this market.

Access full report @ https://www.marketresearchfuture.com/reports/glioblastoma-multiforme-market-12161

Segment Analysis

The global glioblastoma multiforme market is segmented into treatment type, end user and region. The treatment type segment is further segmented into Surgery, Radiation Therapy, chemotherapy, immunotherapy, tumor treating field (TTF) therapy, others. Additionally, the end user is segmented into bronchial diagnosis and bronchial treatment. Furthermore, the end user segment is further segmented into hospitals & clinics, ambulatory surgical centers, others.

Regional Analysis

The global glioblastoma multiforme market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

North America region held over 39.89% of the largest market share in 2021. This is attributed to the robust healthcare infrastructure, substantial R&D investments, and a high prevalence of the disease. For instance, according to National Brain Tumor Society, it is anticipated that over 10,000 people in the United States will die from glioblastoma each year. The five-year survival rate for glioblastoma patients is just 6.9%, and the average duration of survival is expected to be only 8 months. Additionally, along with expanding government support for disease treatment programs and awareness campaigns, the FDA is increasingly approving new pharmaceuticals for the market.

Europe glioblastoma multiforme market is expected to account for the second-largest market share due to the increased focus on early diagnosis and multidisciplinary care of disease in the region. Further, the Germany market of glioblastoma multiforme was attributed to holding the largest market share, and the UK market of glioblastoma multiforme is expected to fastest-growing market in the European region..

The Asia-Pacific glioblastoma multiforme market is expected to grow at the fastest rate from 2023 to 2032. This is due to the growing patient population and expanding healthcare infrastructure in the Asia-pacific region. Moreover, China’s market of glioblastoma multiforme is expected to hold the largest market share, and India market of glioblastoma multiforme is expected fastest-growing market in the Asia-Pacific region.

Furthermore, the Asia-Pacific region immunotherapy is a major trend, with several countries offering it as a treatment option. However, access to advanced treatments varies across Asia-Pacific nations, with disparities in healthcare resources and affordability which is expected to accelerate market growth in the glioblastoma multiforme..

The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of glioblastoma multiforme in the Middle East and Africa are the increase in cases of brain and other nervous system cancers and rise in awareness about chemotherapy treatment in the region that boost the market growth in the Middle East. Moreover. In order to meet unmet medical requirements, international partnerships are investigating ways to increase access to care in these regions. Despite obstacles, glioblastoma multiforme is receiving more attention globally, which is gradually changing the landscape and giving hope to patients in these underdeveloped locations.

Key Findings of the Study

• The global glioblastoma multiforme market is estimated to reach USD 5.65 billion by 2032 at a CAGR of 8.52% during the assessment period.


• North America accounted for the largest share of in 2022. This is due to the robust healthcare infrastructure, substantial R&D investments, and a high prevalence of the disease. and the presence of key players are driving the growth of this market in the North America region.


• Based on treatment type, the radiation therapy segment accounted for the largest share in 2022 and is anticipated to be the fastest growing for the forecast period 2023-2032.


• Based on end users, the hospitals & clinics segment accounted for the largest share in 2022 and is anticipated to be the fastest growing for the forecast period 2023-2032.


• Some of the key players operating in the Glioblastoma multiforme Market are — Merck & Co., Inc (US), Amgen, Inc (US), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc (US), AstraZeneca (UK), Eli Lilly and Company (US), VBI Vaccines Inc. (US), and AbbVie Inc. (US).